411 related articles for article (PubMed ID: 24591761)
21. miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer.
Zubor P; Kubatka P; Dankova Z; Gondova A; Kajo K; Hatok J; Samec M; Jagelkova M; Krivus S; Holubekova V; Bujnak J; Laucekova Z; Zelinova K; Stastny I; Nachajova M; Danko J; Golubnitschaja O
Future Oncol; 2018 Aug; 14(18):1847-1867. PubMed ID: 30019928
[TBL] [Abstract][Full Text] [Related]
22. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential.
Wang W; Luo YP
J Zhejiang Univ Sci B; 2015 Jan; 16(1):18-31. PubMed ID: 25559952
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
24. Genomic Pathology and Biomarkers in Breast Cancer.
Zhang Z; Tang P
Crit Rev Oncog; 2017; 22(5-6):411-426. PubMed ID: 29604921
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.
Zurita M; Lara PC; del Moral R; Torres B; Linares-Fernández JL; Arrabal SR; Martínez-Galán J; Oliver FJ; Ruiz de Almodóvar JM
BMC Cancer; 2010 May; 10():217. PubMed ID: 20487521
[TBL] [Abstract][Full Text] [Related]
26. Small players with big roles: microRNAs as targets to inhibit breast cancer progression.
Greene SB; Herschkowitz JI; Rosen JM
Curr Drug Targets; 2010 Sep; 11(9):1059-73. PubMed ID: 20545613
[TBL] [Abstract][Full Text] [Related]
27. Regulation of breast cancer and bone metastasis by microRNAs.
Vimalraj S; Miranda PJ; Ramyakrishna B; Selvamurugan N
Dis Markers; 2013; 35(5):369-87. PubMed ID: 24191129
[TBL] [Abstract][Full Text] [Related]
28. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction.
Nassar FJ; Nasr R; Talhouk R
Pharmacol Ther; 2017 Apr; 172():34-49. PubMed ID: 27916656
[TBL] [Abstract][Full Text] [Related]
29. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
30. Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression.
Huang Z; Li X; Xie T; Gu C; Ni K; Yin Q; Cao X; Zhang C
Cancer Res Treat; 2020 Oct; 52(4):1067-1083. PubMed ID: 32599985
[TBL] [Abstract][Full Text] [Related]
31. Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression.
Ahadi A
IUBMB Life; 2020 May; 72(5):884-898. PubMed ID: 32078236
[TBL] [Abstract][Full Text] [Related]
32. MicroRNAs and Their Roles in Breast Cancer Bone Metastasis.
Puppo M; Valluru MK; Clézardin P
Curr Osteoporos Rep; 2021 Jun; 19(3):256-263. PubMed ID: 33830428
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential (review).
Zhang K; Zhang Y; Liu C; Xiong Y; Zhang J
Int J Oncol; 2014 Sep; 45(3):950-8. PubMed ID: 24913679
[TBL] [Abstract][Full Text] [Related]
34. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
35. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
36. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
37. RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.
Toda H; Seki N; Kurozumi S; Shinden Y; Yamada Y; Nohata N; Moriya S; Idichi T; Maemura K; Fujii T; Horiguchi J; Kijima Y; Natsugoe S
Mol Oncol; 2020 Feb; 14(2):426-446. PubMed ID: 31755218
[TBL] [Abstract][Full Text] [Related]
38. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
[TBL] [Abstract][Full Text] [Related]
39. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
40. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
